"Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient" by John Godwin

Selected Works of Carlo B. Bifulco, M.D.

Article

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient

Blood (2018)

John Godwin, Providence Portland Medical Center
Carmen Ballesteros-Merino, Providence Cancer Center, Earl A. Chiles Research Institute, PORTLAND, OR
Carlo B Bifulco, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR
Helene Lelièvre, Servier, Paris, France
Jon Wigginton, MacroGenics, Inc., Rockville, MD
Jan K Davidson-Moncada, MacroGenics, Inc., Washington, DC
Bernard Fox, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR

Link

Disciplines

Publication Date

November 29, 2018

DOI

10.1182/BLOOD-2018-99-118522

Citation Information

John Godwin, Carmen Ballesteros-Merino, Carlo B Bifulco, Helene Lelièvre, et al.. "Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient" Blood Vol. 132 (2018) p. 4065 - 4065
Available at: http://works.bepress.com/carlo-bifulco/70/